Amid all these challenges, the strong uptake of Nubeqa (darolutamide), a non-steroidal androgen receptor inhibitor, for treating patients with non-metastatic castration-resistant prostate cancer is a positive. The label expansion of Nubeqa, in combination with docetaxel, for treating patients with metastatic hormone-sensitive prostate cancer will further boost the company's sales.